Membranous nephropathy in patients with HIV: a report of 11 cases.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
18 09 2020
Historique:
received: 08 03 2020
accepted: 23 08 2020
entrez: 19 9 2020
pubmed: 20 9 2020
medline: 21 10 2021
Statut: epublish

Résumé

Membranous nephropathy (MN) has been recognized to occur in patients with human immunodeficiency virus (HIV) infection since the beginning of the HIV epidemic. The prevalence of phospholipase A2 receptor (PLA2R)-associated MN in this group has not been well studied. We conducted a retrospective review of electronic pathology databases at three institutions to identify patients with MN and known HIV at the time of renal biopsy. Patients with comorbidities and coinfections known to be independently associated with MN were excluded. We identified 11 HIV-positive patients with biopsy-confirmed MN meeting inclusion and exclusion criteria. Patient ages ranged from 39 to 66 years old, and 10 of 11 patients (91%) were male. The majority of patients presented with nephrotic-range proteinuria, were on anti-retroviral therapy at the time of biopsy and had low or undetectable HIV viral loads. Biopsies from 5 of 10 (50%) patients demonstrated capillary wall staining for PLA2R. Measurement of serum anti-PLA2R antibodies was performed in three patients, one of whom had positive anti-PLA2R antibody titers. Follow-up data was available on 10 of 11 patients (median length of follow-up: 44 months; range: 4-145 months). All patients were maintained on anti-retroviral therapy (ARV) and 5 patients (52%) received concomitant immunosuppressive regimens. Three patients developed end-stage renal disease (ESRD) during the follow-up period. MN in the setting of HIV is often identified in the setting of an undetectable viral loads, and similar to other chronic viral infection-associated MNs, ~ 50% of cases demonstrate tissue reactivity with PLA2R antigen, which may be seen without corresponding anti-PLA2R serum antibodies.

Sections du résumé

BACKGROUND
Membranous nephropathy (MN) has been recognized to occur in patients with human immunodeficiency virus (HIV) infection since the beginning of the HIV epidemic. The prevalence of phospholipase A2 receptor (PLA2R)-associated MN in this group has not been well studied.
METHODS
We conducted a retrospective review of electronic pathology databases at three institutions to identify patients with MN and known HIV at the time of renal biopsy. Patients with comorbidities and coinfections known to be independently associated with MN were excluded.
RESULTS
We identified 11 HIV-positive patients with biopsy-confirmed MN meeting inclusion and exclusion criteria. Patient ages ranged from 39 to 66 years old, and 10 of 11 patients (91%) were male. The majority of patients presented with nephrotic-range proteinuria, were on anti-retroviral therapy at the time of biopsy and had low or undetectable HIV viral loads. Biopsies from 5 of 10 (50%) patients demonstrated capillary wall staining for PLA2R. Measurement of serum anti-PLA2R antibodies was performed in three patients, one of whom had positive anti-PLA2R antibody titers. Follow-up data was available on 10 of 11 patients (median length of follow-up: 44 months; range: 4-145 months). All patients were maintained on anti-retroviral therapy (ARV) and 5 patients (52%) received concomitant immunosuppressive regimens. Three patients developed end-stage renal disease (ESRD) during the follow-up period.
CONCLUSIONS
MN in the setting of HIV is often identified in the setting of an undetectable viral loads, and similar to other chronic viral infection-associated MNs, ~ 50% of cases demonstrate tissue reactivity with PLA2R antigen, which may be seen without corresponding anti-PLA2R serum antibodies.

Identifiants

pubmed: 32948130
doi: 10.1186/s12882-020-02042-x
pii: 10.1186/s12882-020-02042-x
pmc: PMC7501617
doi:

Substances chimiques

Anti-HIV Agents 0
Autoantibodies 0
PLA2R1 protein, human 0
Receptors, Phospholipase A2 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

401

Références

Am J Nephrol. 2015;41(4-5):345-53
pubmed: 26087695
N Engl J Med. 2009 Jul 2;361(1):11-21
pubmed: 19571279
QJM. 1995 Sep;88(9):627-34
pubmed: 7583076
Am J Nephrol. 2016;43(2):65-70
pubmed: 26914654
Immunol Rev. 2013 Sep;255(1):197-209
pubmed: 23947356
Viruses. 2019 Aug 19;11(8):
pubmed: 31430946
Clin J Am Soc Nephrol. 2013 Sep;8(9):1524-32
pubmed: 23685946
Kidney Int. 2020 May;97(5):1006-1016
pubmed: 32278618
Kidney Int. 2005 Apr;67(4):1381-90
pubmed: 15780090
J Am Soc Nephrol. 2012 Feb;23(2):343-50
pubmed: 22135313
Appl Immunohistochem Mol Morphol. 2018 Sep;26(8):591-598
pubmed: 28362702
J Infect Public Health. 2012 Apr;5(2):207-10
pubmed: 22541271
Clin Microbiol Rev. 2006 Jan;19(1):80-94
pubmed: 16418524
Am J Kidney Dis. 1999 Feb;33(2):282-6
pubmed: 10023639
Mod Pathol. 2013 May;26(5):709-15
pubmed: 23196797
Clin Nephrol. 1995 Sep;44(3):141-7
pubmed: 8556829
Science. 1998 Feb 27;279(5355):1344-7
pubmed: 9478893
Curr Opin Nephrol Hypertens. 2018 May;27(3):144-152
pubmed: 29337702
Nephrol Dial Transplant. 2016 Dec;31(12):2099-2107
pubmed: 26786550
Medicine (Baltimore). 2011 Sep;90(5):289-95
pubmed: 21857365
Int J Mol Sci. 2017 Oct 03;18(10):
pubmed: 28972547
Am J Kidney Dis. 1997 Apr;29(4):514-25
pubmed: 9100039
Am J Kidney Dis. 1997 Jul;30(1):116-9
pubmed: 9214410
J Am Soc Nephrol. 2015 Feb;26(2):302-13
pubmed: 25288605
Arch Intern Med. 1990 Feb;150(2):287-92
pubmed: 2405802
N Engl J Med. 2018 Apr 26;378(17):1655-6
pubmed: 29694807
N Engl J Med. 1991 May 23;324(21):1457-63
pubmed: 2023605
Ann Intern Med. 2003 Aug 5;139(3):214-26
pubmed: 12899589
Nat Rev Nephrol. 2016 May;12(5):291-300
pubmed: 26782145
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1337-1342
pubmed: 27797895
Kidney Int. 1993 Dec;44(6):1327-40
pubmed: 8301934
Kidney Int. 2006 May;69(10):1885-91
pubmed: 16625149

Auteurs

Vivek Charu (V)

Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, H2110A, Stanford, CA, 94304, USA. vcharu@stanford.edu.

Nicole Andeen (N)

Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

Vighnesh Walavalkar (V)

Department of Pathology, University of California at San Francisco, San Francisco, CA, USA.

Jessica Lapasia (J)

Department of Nephrology, The Permanente Medical Group, San Francisco, CA, USA.

Jin-Yon Kim (JY)

Department of Nephrology, The Permanente Medical Group, Sacramento, CA, USA.

Andrew Lin (A)

Department of Nephrology, The Permanente Medical Group, San Francisco, CA, USA.

Richard Sibley (R)

Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, H2110A, Stanford, CA, 94304, USA.

John Higgins (J)

Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, H2110A, Stanford, CA, 94304, USA.

Megan Troxell (M)

Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, H2110A, Stanford, CA, 94304, USA.

Neeraja Kambham (N)

Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, H2110A, Stanford, CA, 94304, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH